TRX-920 / TaiRx - LARVOL DELTA

Study of TRX-920 for Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: TaiRx, Inc. | Trial completion date: Jan 2026 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Study of TRX-920 for Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: TaiRx, Inc.

New P1 trial • Oncology • Solid Tumor

Announcement】TRX-920, a new oral cancer drug of TRX-920, passed the Phase I clinical trial review by the Taiwan Food and Drug Administration (TFDA), and was approved to perform dose-escalation trials for advanced tumors. [Google translation] (stock.yahoo) - "...Tairui's new oral cancer drug TRX-920 has passed the Phase I clinical trial review by the Taiwan Food and Drug Administration (TFDA), and has been approved to perform dose-escalation trials for advanced tumors."

New P1 trial • Oncology • Solid Tumor

[Announcement] Tairui submitted an application to the Taiwan Food and Drug Administration (TFDA) for the Phase I dose-escalation trial of the new oral cancer drug TRX-920 for advanced solid tumors. [Google translation] (stock.yahoo) - "Tairui submitted an application to the Taiwan Food and Drug Administration (TFDA) for the first phase dose-escalation trial of the new oral cancer drug TRX-920 for advanced solid tumors....The trial industry was approved by the US FDA after review, and continued to apply to TFDA to implement the first phase in the Taiwan Clinical Trial Center....The clinical trial plan will carry out the safety assessment and human pharmacokinetic study of TRX-920 oral formulation." "

IND • New P1 trial • Oncology • Solid Tumor